Lilly Just Paid $85M to Teach Your Immune System Some Manners
Eli Lilly just dropped $85 million upfront, with $1.84 billion more on the table, to partner with Repertoire Immune Medicines on a radical idea: retraining the immune system instead of suppressing it. If it works, autoimmune patients might finally escape lifelong drug regimens.
Every autoimmune drug on the market right now works on the same basic principle: your immune system is attacking your own body, so we're going to hit the brakes on the whole thing. It's like shutting down an entire highway because one driver is going the wrong way. It works, kind of, but it leaves patients vulnerable to infections, stuck on drugs for life, and never truly in remission.
Eli Lilly just bet nearly $2 billion that there's a better way.
The Big Idea: Don't Suppress, Retrain
Lilly has entered a strategic collaboration with Repertoire Immune Medicines, a Cambridge-based biotech, paying $85 million upfront with up to $1.84 billion in additional milestones tied to development and commercial progress. Add in tiered royalties on any future sales, and this is one of the richest tolerance-focused deals in pharma history.
But the money isn't the interesting part. The concept is.
Repertoire is building something called tolerizing therapies: treatments designed to teach the immune system to stop attacking the body's own tissues. Instead of sledgehammering the entire immune response into submission, the idea is to retrain specific rogue cells. Think of it less like sedating an angry dog and more like actually training it not to bite.
If that sounds too good to be true, it's worth noting that the 2025 Nobel Prize in Medicine went to researchers who discovered regulatory T cells, the immune system's natural peacekeepers. The science behind immune tolerance isn't theoretical anymore; it's accelerating.
Repertoire's Secret Weapon
At the center of this deal is Repertoire's DECODE platform, a technology suite that maps the precise interactions between T cells and the antigens that set them off. In plain English, DECODE figures out exactly which immune cells are misbehaving and what's triggering them.
That specificity is the whole game. Traditional autoimmune drugs cast a wide net: They suppress large swaths of the immune system, which is why patients on drugs like methotrexate or biologics face higher infection risk. Repertoire's approach is more like a sniper rifle than a carpet bomb; it identifies the disease-driving immune signals and targets only those.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The company is developing mRNA-based tolerizing vaccines that expand regulatory T cells (the peacekeepers) and dial down the specific T cells causing damage. The goal isn't just symptom control, it's durable remission, potentially resetting a patient's immune system back to a healthier baseline.
Repertoire CEO Torben Straight Nissen put it in ambitious terms, saying the collaboration offers the chance to create "potentially paradigm shifting new medicines" that address "the root cause of the immune dysregulation."
How the Deal Actually Works
The structure tells you a lot about how both sides view the risk.
Repertoire leads the research phase. Using DECODE, they'll identify T cell-targeting therapies for undisclosed autoimmune diseases and push them to the development candidate stage. Once a candidate is nominated, Lilly takes the wheel: clinical trials, manufacturing, regulatory filings, and global commercialization.
The milestone-heavy payout structure is classic big pharma risk management. That $85 million upfront is real commitment, but the remaining $1.84 billion only flows if the science actually delivers. It's conviction with guardrails: Lilly is saying "we believe in this, but we're not writing a blank check."
The specific autoimmune diseases being targeted haven't been disclosed, which is typical for early-stage platform deals.
Why Lilly Is Going All-In on Immunology
This isn't a one-off for Lilly. The Repertoire deal is actually their second immunology move of 2026, following an earlier acquisition of Ventyx Biosciences for its NLRP3 inhibitors. Two deals in one month signals a company that's building an entire autoimmune franchise, not just dabbling.
And the market they're chasing is enormous. Autoimmune therapeutics were valued at $168.6 billion in 2025 and are projected to hit $226 billion by 2035. With over 1,300 new assets in the pipeline industry-wide and an 18% jump in clinical trial activity last year, this space is white-hot.
But most of that market is still dominated by immunosuppressants: drugs that manage symptoms rather than address root causes. If tolerance-based therapies can deliver even a fraction of their promise, they could eat into that dominance in a massive way.
Repertoire Is Collecting Big Pharma Partners Like Pokémon
Lilly isn't the first major player to write a big check for Repertoire's platform. The company already has deals with Bristol Myers Squibb (worth up to $1.8 billion, signed in April 2024), Roche's Genentech ($35 million upfront plus up to $730 million in milestones), and Pfizer. In total, Repertoire has raised more than $350 million from investors.
When four of the world's largest pharma companies are independently betting on the same platform, it's worth paying attention. Each partnership typically covers different disease areas or therapeutic modalities, so there's less overlap than you'd think. But the collective signal is clear: the industry is moving toward tolerance.
The Catch (Because There's Always a Catch)
The immune tolerance field is still early. Most approaches (nanoparticle-based therapies, engineered regulatory T cells, antigen-specific vaccines) are in preclinical or early clinical stages. Companies like Anokion, Sonoma Biotherapeutics, and Quell Therapeutics are all chasing similar goals with different technologies, and nobody has delivered a late-stage clinical win yet.
The most impressive tolerance-adjacent results have come from CAR-T therapy in lupus, where patients achieved drug-free remission after treatment wiped out their autoreactive immune cells and allowed the system to reset. But that's a different mechanism than what Repertoire is building, and it's still early data.
Repertoire's mRNA tolerizing vaccines need to prove they can selectively expand the right regulatory T cells and shut down the right effector T cells: in humans, at scale, across multiple diseases. That's a tall order. Phase 2 remains a well-known bottleneck for the autoimmune field, and long-term human data on tolerance approaches is still thin.
The Bottom Line
Lilly's deal with Repertoire isn't about buying a drug. It's about buying into a new treatment philosophy, one where autoimmune patients aren't chained to immunosuppressants for life but instead get their immune systems reprogrammed to stop the attack at its source.
The milestone-heavy deal structure means Lilly can walk away if the science stalls. But the $85 million upfront, and the broader pattern of big pharma piling into this space, suggests the smart money thinks immune tolerance is more than a pipe dream.
Autoimmune disease affects roughly 1 in 10 people worldwide. If tolerizing therapies eventually work, they won't just be a new product category; they'll be a completely different way of thinking about treatment. Lilly is betting nearly $2 billion that the immune system can learn new tricks. The next few years will tell us if they're right.
Deals & M&A
5 min read
Moderna Just Sold a Rare Disease Drug for Pennies on the Dollar
Moderna handed Recordati the commercial rights to a potentially first-in-class rare disease therapy for just $50 million upfront. Leerink analysts called it a "garage sale," and the math backs them up.
